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Recently, we observed that lipopolysaccharide (LPS) suppresses corpus luteum (CL) function 
in isolated perfused ovaries. It remained unclear if this suppression was due to an increased 
luteal PGF2α-secretion or an LPS-induced apoptosis. Therefore, possible impacts of PGF2α 
and LPS were inhibited by a non-steroidal anti-inflammatory drug (flunixin) and an 
endotoxin-binding agent (polymyxin), respectively. Bovine ovaries with a mid-cycle CL were 
collected after slaughter and perfused for 240min. After 50min of equilibration, flunixin and 
polymyxin B (5μg/mL of each) were added to the perfusion medium of six ovaries 
respectively. All ovaries were treated with E.coli LPS (0.5μg/mL) 60min after the onset of 
perfusion, and received 500I.U. of human chorionic gonadotropin (hCG) after 120min of 
perfusion. Progesterone and PGF2α were measured in the effluent perfusate every 10 and 
30min, respectively. Biopsies of the CL were collected every 60min to determine the mRNA 
expression of the cytokine TNFA and factors of apoptosis (CASP3, -8). Flunixin-treatment 
inhibited the increase of PGF2α after LPS-challenge that was observed in the polymyxin-
treated (PX-LPS) ovaries. After hCG-stimulation, progesterone secretion increased (P<0.05) 
in group PX-LPS but not in the flunixin-treated (F-LPS) ovaries. Compared to the initial 
values before LPS-challenge, luteal mRNA expression of TNFA and CASP3 was increased 
(P<0.05) in group F-LPS at 120 and 180min, respectively, and those of CASP8 was decreased 
(P<0.05) in group PX-LPS at 60 and 120min after LPS-treatment. In conclusion, complete 
inhibition of any impact of PGF2α by flunixin did not prevent LPS-induced apoptosis. 






Lipopolysaccharid (LPS) hemmt die Funktion des Corpus luteum in isoliert perfundierten 
Ovarien. Es ist unklar, ob diese Hemmung auf einer erhöhten lutealen PGF2α-Sekretion oder 
LPS-induzierten Apoptose beruht. Daher wurden PGF2α und LPS durch ein NSAID (Flunixin) 
bzw. einen Endotoxinfänger (Polymyxin) inhibiert. Bovine Ovarien mit Blütegelbkörper 
wurden am Schlachthof entnommen und während 240min perfundiert. Nach 50min 
Äquilibrierung wurden Flunixin bzw. Polymyxin B (je 5µg/ml) zum Perfusionsmedium von je 
sechs Ovarien hinzugefügt. Alle Ovarien wurden 60min nach Perfusionsbeginn mit E.coli 
LPS (0,5μg/ml) behandelt und erhielten nach 120min Perfusion 500I.E. hCG. Progesteron 
(P4) und PGF2α wurden alle 10 bzw. 30min im abfliessenden Perfusat gemessen. 
Gelbkörperbioptate zur Bestimmung der mRNA Expression des Zytokins TNFA und der 
Apoptosemarker (CASP3, -8) wurden alle 60min entnommen. Die Flunixin-Behandlung 
hemmte den Anstieg von PGF2α nach LPS-Stimulation, der bei mit Polymyxin behandelten 
Ovarien (PX-LPS) beobachtet wurde. Nach hCG-Stimulation stieg die P4-Sekretion in Gruppe 
PX-LPS an, aber nicht bei den mit Flunixin behandelten Ovarien (F-LPS). Die luteale mRNA 
Expression von TNFA und CASP3 nahm in Gruppe F-LPS zu, während die Expression von 
CASP8 in Gruppe PX-LPS abnahm. Zusammengefasst verhindert eine Inhibition von PGF2α 
durch Flunixin die LPS-induzierte Apoptose nicht, während Polymyxin die luteale 
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Inflammatory diseases, such as endometritis and mastitis, play a pivotal role among diseases 
in dairy cows and reduce their reproductive performance (Barker et al. 1998, LeBlanc et al. 
2002). To investigate the effects of inflammation on cows’ fertility, treatment with 
lipopolysaccharide (LPS), the endotoxin from the outer membrane of gram-negative bacteria, 
was used as a model (Suzuki et al. 2001, Lavon et al. 2008, Williams et al. 2008, Herzog et 
al. 2012, Lüttgenau et al. 2016a, Lüttgenau et al. 2016b). During inflammation, LPS induces 
the production of prostaglandins (PGs) by macrophages, monocytes and endothelial cells 
(Andreasen et al. 2008). Furthermore, LPS activates the nuclear factor kappa B (NF-κB), 
which leads to the expression of many proinflammatory cytokines (Tsuzuki et al. 2001). 
These cytokines are released from the activated macrophages and stimulate in turn the 
neutrophils to produce reactive oxygen species (Er et al. 2009). Moreover, it is noteworthy 
that some cytokines, such as tumor necrosis factor α (TNFA) and interferon (IFN) γ, may 
directly reduce fertility due to their cytotoxic effect on luteal cells (Petroff et al. 2001). 
When given intravenously, Escherichia coli (E. coli) LPS transiently reduced size and 
blood flow of the bovine corpus luteum (CL), as well as blood progesterone (P4) 
concentrations (Herzog et al. 2012). Since PGF2α metabolite concentrations were also 
increased after LPS treatment (Herzog et al. 2012), it was speculated that an enhanced uterine 
release of PGF2α induced premature luteolysis. However, LPS induced apoptosis in luteal 
monolayer cultures (Mishra & Dhali 2007), although an influence of endometrium-derived 
PGF2α was excluded. Therefore, a recent study (Lüttgenau et al. 2016c) used the in vitro 
model of a perfused ovary to investigate whether the LPS-induced effects on the bovine CL 
were mediated via LPS-induced release of PGF2α or directly by LPS. In that study, the 
reduced P4 secretion seemed to be caused predominantly by an increase in LPS-induced 
apoptosis, but an impact of luteal PGF2α could not be excluded. 
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To further investigate the impact of luteal PGF2α and LPS on luteolytic effects, an 
attempt was made in the present study to inhibit their different modes of action by a non-
steroidal anti-inflammatory drug (NSAID) and an endotoxin-binding agent, respectively. 
The NSAID flunixin inhibits the enzyme cyclooxygenase and therefore blocks the 
synthesis of the eicosanoid inflammatory mediators, such as PGs (Vane 1971, Cheng et al. 
1998). Furthermore, flunixin has antioxidative properties (Konyalioglu et al. 2007), and 
inhibits the activation of NF-κB (Bryant et al. 2003) and the increase in cytokine levels 
(Yazar et al. 2007, Chalmeh et al. 2013). In LPS-treated mice, for instance, flunixin inhibited 
the increase in TNFA, interleukin 1β, and interleukin 10 (Yazar et al. 2007). However, 
flunixin does not have the ability to bind directly the LPS molecule (Parviainen et al. 2001). 
The use of flunixin for the treatment of endotoxemia relies on its modulatory function on 
acute hemodynamic changes (Chalmeh et al. 2013). 
Polymyxin B is an antibiotic with endotoxin-binding properties due to its high affinity 
to the lipid A of LPS (Morrison & Jacobs 1976, Cavaillon & Haeffner-Cavaillon 1986, 
Bucklin et al. 1995). In human medicine, polymyxin B was successfully used to reduce blood 
endotoxin levels in patients with sepsis (Uriu et al. 2002, Cruz et al. 2007, Cruz et al. 2009). 
In this respect, 1 mg of E. coli LPS is bound by 55 µg of polymyxin B (Morrison & Jacobs 
1976). However, polymyxin B not only binds LPS but also inhibits the binding activity of 
NF-κB, and therefore inhibits the new expression of TNFA (Tsuzuki et al. 2001). 
In summary, flunixin inhibits the LPS-induced PGF2α secretion by the bovine CL, 
whereas polymyxin B can directly bind and inactivate the LPS molecule. Furthermore, both 
drugs inhibit cytokine production. Using separate treatments with flunixin and polymyxin B 
in the isolated perfused ovary model, the present study investigates if luteolysis due to 
endotoxemia is mediated predominantly by luteal PGF2α or by LPS-induced apoptosis. 
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Ovaries with mesovarium were harvested from the carcasses of clinically healthy cows 
(Bos taurus; including Brown Swiss, Holstein Friesian, Red Holstein and Swiss Fleckvieh) 
that were slaughtered at a commercial abattoir. Twelve ovaries containing a CL with an 
estimated diameter of >20 mm (subsequently confirmed as a mid-cycle CL) and intact tunica 
albuginea as well as mesovarium with ovarian vessels were used. 
 
2.2. Preparation of ovaries 
 
Immediately after the ovary was recovered, the ramus uterinus and all branches of the 
ovarian artery with a similar diameter were ligated (Polysorb 0®; Corvidien, Dublin, Ireland), 
and a 16-gauge venous catheter (Vygonüle T; Vygon, Écouen, France) was fixed within the 
ovarian artery with three circular ligatures (Polysorb 0®). The preparation and catheterization 
of the ovarian artery, the flushing of the ovary, and its transport to the laboratory was recently 
described in detail (Lüttgenau et al. 2016c). 
In the laboratory, the ovary with vascular pedicle was weighed using a precision balance 
(Mettler PM 400®; Mettler-Toledo, Greifensee, Switzerland), and the average diameter of the 
CL was determined with ultrasonography (Aquila Esaote Pie Medical; Esaote Biomedica, 
Cologne, Germany). Only ovaries with a luteal diameter >20 mm were used. 
 




Ovaries were fixed on the bipod as described recently (Lüttgenau et al. 2016c). An 
incubator for newborn humans (Atom Infant Incubator V-850; Atom Medical Corporation, 
Tokyo, Japan) and an advanced (compared to Lüttgenau et al. 2016c) perfusion system were 
used to ensure a controlled perfusion under standardized microclimatic conditions 
(temperature, 37.5 to 38.5 °C; relative humidity, 75 to 85 %). A schematic illustration of the 
complete set-up is shown (Fig. 1). 
As medium for the isolated perfusion of the ovary, a modified Tyrode’s solution was 
used (for detailed composition see Lüttgenau et al. 2016c). Tyrode’s solution was oxygenated 
with carbogen (Oxycarbon medizinal; Carbagas, Domdidier, Switzerland) using a membrane 
oxygenator (Radnoti Membrane Oxygenating Chamber; Radnoti Limited, Dublin, Ireland). 
To ensure adequate oxygenation, the pH and partial pressures of oxygen and carbon dioxide 
in the perfusion medium were measured before and after its passage through the ovary. 
Measurements were performed at the start of perfusion and then every 60 min until the end of 
perfusion using a blood-gas analysis system (Rapidlab 248 TM; Siemens, Munich, Germany). 
According to the results of blood-gas analysis, the supply of carbogen and the flow rate were 
adjusted to sustain a physiologic pH (target value, 7.40). The perfusion medium was heated in 
water jacketed reservoirs (Water-Jacketed Reservoir 3 L and 5 L; Radnoti Limited) by a 
heated circulating bath (Immersion Thermostats, Baths and Circulators, Optima T100; Grant 
Instruments Ltd, Cambridgeshire, UK). Water jacketed glasswares and tubings (Water-
Jacketed f/tzbe ass 24’’, Water-Jacketed Oxygenator, Water-Jacketed Bubble Trap; Radnoti 
Limited) kept the temperature of the perfusion medium constant until it reached the ovary. 
Every 10 min, the temperature of the perfusion medium was measured directly before 
entering the ovarian artery, by inserting a thermometer in the perfusion system. According to 
these measurements, temperature of the water circulation was adjusted to maintain the 
medium’s temperature between 37 and 38 °C. 
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For perfusion, a volume- and pressure-controlled peristaltic pump (Minipuls 3 
Peristaltic Pump; ADInstruments, Oxford, UK) was used. The peristaltic pump was connected 
to a pump speed controlling hardware device (STH Pump Controller), a data acquisition 
hardware (PowerLab), and a bridge amplifier (Bridge Amp) that allowed to connect the 
PowerLab to the pressure transducer (Physiological Pressure Transducer; all from 
ADInstruments). The PowerLab was connected via USB to a laptop, where data acquisition 
and analysis software (LabChart 8; ADInstruments) was installed. The flow was manually 
calibrated with a measuring cylinder and a chronograph prior to the start of each experiment, 
and the data was inserted in the LabChart software that allowed to continuously measure and 
possibly modify the flow of the perfusion medium. The pressure was measured with the 
transducer that was inserted in the perfusion system close to accessing the ovarian artery. The 
pressure transducer was connected to the PowerLab, Bridge Amp and STH Pump Controller, 
which in turn were connected to the LabChart software. The pressure was calibrated with the 
help of a transducer simulator and tester (Delta-Cal; Utah Medical Products Inc., Athlone, 
Ireland) and the data was inserted in LabChart. The pressure was continuously measured 
throughout the experiment. The flow was adjusted to achieve a value of approximately 
2 mL/min per gram ovarian tissue, as proposed (Stähler & Huch 1971). To avoid artifacts 
caused by accumulation of metabolites or hormones, the perfusion medium was not recycled. 
 
2.4. Study design 
 
All ovaries were perfused for 240 min. During the first 50 min (equilibration), no agents 
were added to the perfusion medium. Ovaries were randomly allocated to two different 
groups of six ovaries. In group F-LPS 5 µg/mL flunixin (Flunixine Biokema ad us. vet.; 
Biokema SA, Crissier, Switzerland) and in group PX-LPS 5 µg/mL polymyxin B (Polymyxin-
B-sulfat KA 10 Mio IE/100 mL ad us. vet.; Kantonsapotheke Zürich, Zurich, Switzerland) 
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were added to the medium, starting at 50 min after the start of perfusion. In both groups, 
0.5 µg/mL E. coli O55:B5 LPS (Sigma-Aldrich, St. Louis, MO, USA) were given to the 
medium at 60 min after the start of perfusion. Flunixin, polymyxin B, and LPS treatments 
were continued until the end of the perfusion time. For all ovaries, human chorionic 
gonadotropin (hCG, 500 I.U.; Chorulon 1500®; MSD Animal Health GmbH, Luzern, 
Switzerland) was added to the perfusion medium at 210 min after the start of perfusion. 
 
2.5. Lactate, creatine kinase, P4, PGE2, and PGF2α 
 
Effluent perfusion medium was sampled every 10 min throughout the entire perfusion 
period. At each time of sampling, three native aliquots were collected and stored at -20 °C. 
To ensure that the ovary remained in a physiological state, lactate concentration and 
activity of creatine kinase (CK) were used as markers of hypoxia and cell death (Richter et al. 
2000; Lüttgenau et al. 2016c). For these measurements, which were performed every 30 min 
during the perfusion period, the Cobas Mira Plus analyzer (Roche, Basel, Switzerland) was 
used as described recently (Lüttgenau et al. 2016c). 
Concentrations of P4 were measured in the effluent perfusion medium every 10 min 
throughout the perfusion period, using a radioimmunoassay (Kit RIA immunotech IM1188 lot 
150817C; Beckman Coulter GmbH, Krefeld, Germany). The range of standard concentrations 
for this test was 0.03 to 53 ng/mL, intra- and inter-assay coefficients of variation were ≤8.5 % 
and ≤8.7 %, respectively, and 50 % of relative binding (ED50) occurred at 1.56 to 
1.77 ng/mL. 
Starting at 60 min of perfusion, concentrations of PGE2 and PGF2α were measured every 
30 min in the effluent perfusion medium. Therefore, high-sensitivity ELISA kits (Enzo Life 
Sciences AG, Lausen, Switzerland) were used. For PGE2 and PGF2α tests, the range of 
standard concentrations was 7.81 to 1000 pg/mL and 1.95 to 2000 pg/mL, respectively. Intra- 
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and inter-assay coefficients of variation were ≤9.8 and ≤12.6 % for PGE2 and ≤7.2 and 
≤11.0 % for PGF2α, respectively, and ED50 for PGE2 and PGF2α occurred at 127.8 pg/mL and 
81 pg/mL, respectively. 
 
2.6. Corpus luteum biopsy and expression analysis 
 
One biopsy sample (approximately 15 x 1 x 1 mm) was obtained from the maximum 
diameter (including cells from the periphery and the center) of the CL after 60, 120, 180, and 
240 min of perfusion. A detailed description of the collection and storing of luteal samples 
was provided recently (Lüttgenau et al. 2016c). 
Luteal mRNA expression was determined for the proinflammatory cytokine TNFA, the 
apoptotic enzymes caspase (CASP) 3 and -8, and the PGE- (PGES/PTGES) and PGF 
(PGFS/AKR1B1) synthases. 
Total RNA from luteal tissue samples was extracted using the miRNeasy Mini Kit 
(Qiagen). Homogenization of the tissues was achieved with the Qiagen TissueLyser II and 
2.8 mm ceramic beads (2 mL Reinforced Tubes w/ 2.8 mm Ceramic Beads 50 Pack; 
LabForce, Muttenz, Switzerland). RNA concentration and integrity were quantified using the 
NanoDrop 2000 (peqLab) and the Bioanalyzer 2100 (Agilent Technologies, Waldbronn, 
Germany), respectively. RNA integrity numbers ranged from 9.1 to 10.0 (average 9.9). Five 
hundred nanograms of RNA were reverse transcribed using the M-MLV Reverse 
Transcriptase, RNase H Minus, Point Mutant (Promega, Madison, WI, USA) as recently 
described (Pistek et al. 2013). 
Luteal mRNA expression was determined in a two-step quantitative real-time PCR (qPCR) 
using the CFX384 Real-Time PCR Detection System (Bio-Rad, Munich, Germany) and the 
Kapa SYBR Fast Universal qPCR Kit (KK4618; Kapa Biosystems, London, UK). The qPCR 
was performed in a reaction volume of 10 µL, consisting of 5 µL Kapa SYBR Fast Universal 
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qPCR Kit, 0.4 µL of each primer (10 µM), 0.07 µL VisiBlue (TATAA Biocenter, Göteborg, 
Sweden), 3.13 µL water, and 1 µL cDNA. The primers used to amplify specific fragments 
referring to selected regulated genes are shown in Table 1. The primer-specific annealing 
temperatures are outlined. The cycle number (Cq) required to achieve a definite SYBR Green 
fluorescence signal was calculated by the regression method (Bio-Rad CFX Manager 3.1). 
The Cq was inversely correlated with the logarithm of the initial template concentration. The 
Cq determined for the target genes were normalized against the geometrical mean of the five 
reference genes YWHAZ, H3F3A, CNOT11, SUZ12 and TBP (ΔCq). To avoid negative digits, 
while allowing the estimation of a comparison between two genes, data were presented as 
means ± SEM added to the arbitrary value 10 (ΔCq). Thus, a high ΔCq proportionally 
resembled high transcript abundance (Livak and Schmittgen, 2001). 
 
2.7. Postprocessing of ovaries 
 
After the 240-min study period, ovaries with mesovarium were weighed again to 
estimate perfusion-induced edema. Subsequently, all ovaries (except one from group F-LPS) 
were perfused with stained (Patent blue; Sigma-Aldrich) perfusion medium and dissected to 
test for smaller leakages and homogenous staining of the CL. In the experiments, less than 
one-quarter of perfusion medium leaked from the ovarian artery before reaching the ovary and 
the CL was homogenously stained; therefore, all ovaries were included in the study. Between 
each perfusion of an ovary, all glassware and tubing that were in contact with the perfusion 
medium were cleaned and steam sterilized. 
 




The median (± mean absolute deviation, MAD) interval between death of the cow and 
begin of the perfusion was 59.0 ± 2.2 min (range, 47 – 72 min) and did not differ (P > 0.05) 
between groups F-LPS and PX-LPS. The mean (± SEM) diameter of the CL was 28.0 ± 
1.2 mm and did not differ (P > 0.05) between the groups. Based on their dimensions, CL were 
designated as mid-cycle (Days 8-16; Day 1 = ovulation) according to Herzog et al. (2010). 
The perfusion pressure was measured in 11 out of 12 ovaries; in one ovary from group 
F-LPS measurement was not possible due to technical problems. The mean (± SEM) pressure 
was 121.6 ± 3.6 mmHg and there was no treatment or time effect (P > 0.05). The temperature 
and the flow of the perfusion medium did not differ between the groups (P > 0.05) and the 
mean (± SEM) temperature and median (± MAD) flow were 37.19 ± 0.05 °C and 34 ± 
3.3 mL/min, respectively. 
All ovaries showed contractions of the vascular pedicle that were not quantified. A 
subjective intensification of the contractions over time was observed in both groups. During 
perfusion, ovaries with vascular pedicle increased in weight due to edema in the mesovarium. 
The mean (± SEM) increase was 56.7 ± 7.8 g and did not differ (P > 0.05) between groups. 
Analyses of lactate, CK, PGE2, and PGF2α had lower detection limits of 0.04 mmol/L, 
5 U/L, 72 pg/mL, and 2.0 pg/mL, respectively. For measurements below these limits, 
0.03 mmol/L, 4 U/L, 71 pg/mL, and 1.9 pg/mL were used as arbitrary values for lactate, CK, 
PGE2, and PGF2α, respectively, to facilitate statistical analysis. Additionally, for PGE2 
measurements above the higher detection limit of 10,000 pg/mL, the arbitrary value of 
10,001 pg/mL was used. 
Statistical analyses were conducted using the Statistical Analysis System V9.3 (SAS 
Institute Inc., Cary, NC, USA). The distribution of the data was tested for normality by means 
of the Shapiro-Wilk-test (PROC UNIVARIATE). Repeated measures ANOVA (PROC GLM) 
was performed to assess the influence of treatment, time, and treatment*time interaction. 
Significant results were further evaluated using a Student’s t-test (PROC MEANS) for 
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dependent pairwise comparisons and a single-factor ANOVA (PROC GLM) for independent 
pairwise comparisons. In case of non-normal data, Wilcoxon’s signed rank test (PROC 
UNIVARIATE) for dependent pairwise comparisons and Kruskal-Wallis-test (PROC 
NPAR1WAY) for independent pairwise comparisons were used. Data were presented as 
mean ± SEM or median ± MAD, depending on the distribution of the data, and differences 





Ovarian lactate production and CK activity did not show a treatment (P > 0.05) but a 
time effect (P < 0.0001 and P = 0.0012, respectively). Mean (± SEM) lactate concentrations 
decreased from 0.45 ± 0.06 mmol/L during the equilibration time to 0.18 ± 0.01 mmol/L 
during the treatment period. Similarly, CK activity decreased from 65.9 ± 13.8 U/L during the 
equilibration time to 9.5 ± 1.3 U/L during the treatment period. 
Regarding PGE2 and PGF2α concentrations in the effluent perfusate, there was a 
treatment (P = 0.0004 and P = 0.0002, respectively) and a time effect (P < 0.0001 and 
P = 0.0001, respectively). Concentrations of PGE2 and PGF2α were higher in group PX-LPS 
compared to group F-LPS (Fig. 2A and B). Over time, PGE2 and PGF2α levels increased in 
group PX-LPS (P = 0.03; Fig. 2A and B), whereas levels did not differ in group F-LPS 
(P > 0.05; Fig. 2A and B). 
Progesterone concentrations in the effluent perfusate did not differ neither between the 
treatment groups nor over time (both P > 0.05). On a per-day basis, P4 concentrations in group 
F-LPS started to decrease during LPS-challenge and reached lower levels (P < 0.04) at the 
time of hCG stimulation compared with the start of the treatment period. In group PX-LPS, an 
increase (P < 0.05) in P4 levels was observed at 20 and 30 min after hCG stimulation (Fig. 3). 
Luteal mRNA abundance of TNFA did not show a treatment effect (P > 0.05). 
However, an increase (P = 0.04) in TNFA mRNA was observed between 0 and 120 min after 
LPS-challenge in group F-LPS (Fig. 4A), whereas no difference (P > 0.05) over time was 
found in group PX-LPS. 
Luteal mRNA expression of CASP3 did not show a treatment (P > 0.05) but a time 
effect (P = 0.08). Increased CASP3 mRNA (P < 0.03) was observed in group F-LPS at 
180 min (compared with 0 min) after the start of treatment (Fig. 4B), whereas the expression 
of CASP3 did not differ (P > 0.05) over time in group PX-LPS. 
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The mRNA expression of CASP8 did not differ (P > 0.05) between the groups. Over 
time, CASP8 mRNA remained stable (P > 0.05) in group F-LPS, whereas a decreased 
expression (P < 0.05) at 60 and 120 min after LPS-challenge compared to the start of the 
treatment period was observed in group PX-LPS (Fig. 4B). 
Luteal mRNA expression of PGES and PGFS did not show a treatment effect 
(P > 0.05). Furthermore, the mRNA abundance of PGES and PGFS after LPS-challenge did 





In this experiment, all ovaries had an ischemic time period of less than 72 min before 
re-perfusion. The critical ischemic time was previously determined to be 120 min in rat 
ovaries (Coskun et al. 2009). Furthermore, high lactate concentration and CK activity at the 
start of perfusion, indicating hypoxia and cell death (Ahrén et al. 1972), decreased rapidly 
during the equilibration time and remained stable at low levels during the treatment period. 
The same observation was made in previous studies after successful re-perfusion and 
oxygenation of human uteri (Richter et al. 2000) and bovine ovaries (Lüttgenau et al. 2016c). 
Additionally, the advanced perfusion system in the present study, using an infant incubator, 
water jacketed glassware and tubing, and specific controlling hard- and software, allowed to 
maintain highly standardized conditions for the ovaries. Thus, in our opinion, the results 
obtained during the treatment period of the present study are reliable. 
The synthesis of PGE2 and PGF2α was inhibited in group F-LPS due to the treatment 
with the cyclooxygenase inhibitor flunixin. In contrast, there was a significant increase in 
PGE2 and PGF2α production in group PX-LPS. The CL is rich in arachidonic acids, the 
precursor of PGs, and luteal PGs contribute to the regulation of the CL (Arosh et al. 2004). 
Since PGE2 is a luteotropic factor (Arosh et al. 2004), the inhibition of its synthesis can be 
judged as a detrimental effect of flunixin on the CL. In a recent study (Lüttgenau et al. 
2016c), the impact of luteal PGF2α on the LPS-induced apoptosis of the CL could neither be 
proved nor excluded. In the present study, the complete inhibition of any impact of PGF2α in 
group F-LPS did not prevent LPS-induced apoptosis. Consequently, luteal PGF2α does not 
seem to be responsible for luteolysis after LPS-challenge. However, it is noteworthy that 
PGF2α of different origin, namely luteal and endometrial, is supposed to play a differing role 
in bovine luteal function (Kobayashi et al. 2001, Skarzynski et al. 2001, Shirasuna et al. 
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2004). Therefore, conclusions regarding the impact of luteal PGF2α on the CL cannot 
necessarily be adapted to the effect of endometrial PGF2α. 
From the start of the treatment period until hCG-challenge, P4 concentrations in the 
effluent perfusate remained statistically unchanged in group PX-LPS but decreased in group 
F-LPS. Furthermore, after the application of hCG, P4 levels increased significantly in group 
PX-LPS but not in group F-LPS. In a recent study (Lüttgenau et al. 2016c), LPS abolished the 
hCG-induced increase in P4 that was observed in untreated controls. The inhibition of the 
LPS-induced suppression of hCG-stimulated P4 secretion in group PX-LPS indicates the 
maintenance of luteal viability and hCG responsiveness due to the treatment with 
polymyxin B. In contrast, the treatment with flunixin in group F-LPS was apparently not able 
to block the LPS-induced suppression of luteal responsiveness to hCG. Several in vivo studies 
(Aké-López et al. 2005, Guzeloglu et al. 2007, Geary et al. 2010, von Krueger & Heuwieser 
2010) have already investigated the effect of flunixin on luteal phase length and on 
maintenance of pregnancy but the results were controversial. Some studies revealed an 
increase of luteal phase length and a positive effect on the maintenance of early pregnancy 
(Aké-López et al. 2005, Guzeloglu et al. 2007), whereas other studies did not find any effect 
on early embryonic loss or pregnancy rates (Geary et al. 2010, von Krueger & Heuwieser 
2010). However, detrimental effects of flunixin itself on the CL have not been described yet. 
Therefore, we assume that the suppressed hCG responsiveness of the CL was caused by the 
detrimental effects of LPS that were not inhibited by the flunixin treatment.  
Luteal mRNA expression of TNFA was significantly increased at 120 min compared to 
0 min after the start of LPS treatment in group F-LPS. The increase in TNFA mRNA after 
pretreatment with flunixin indicates that an inhibition of PG synthesis does not avoid the LPS-
induced increase in the expression of proinflammatory cytokines. Since TNFA is known to 
have cytotoxic effects on luteal cells (Petroff et al. 2001), an inhibition of LPS-induced 
apoptosis of the CL by flunixin is not likely. Consistently, flunixin treatment did not inhibit 
19 
 
the LPS-induced suppression of hCG responsiveness of the CL. In group PX-LPS, no 
difference in the mRNA expression of TNFA was found during the treatment period, 
indicating that polymyxin B is more suitable to inhibit the LPS-induced expression of 
proinflammatory cytokines. 
A significant increase in the mRNA expression of the apoptotic marker CASP3 was 
observed in group F-LPS, whereas mRNA abundance of CASP8 decreased transiently in 
group PX-LPS. Both results contribute to the increasing evidence that polymyxin B treatment 
is more suitable than flunixin treatment to inhibit the LPS-induced apoptosis of the bovine 
CL. 
Although flunixin inhibited the synthesis of PGE2 and PGF2α, the luteal mRNA 
expression of PGES and PGFS was not reduced. It is known that luteal PGES shows an 
irregular pattern during the different phases of the luteal phase, whereas PGFS is expressed at 
a constant level throughout the CL lifespan (Arosh et al. 2004). However, the synthesis of 
PGE2 and PGF2α is not closely related to the expression of PGES and PGFS, respectively. 
In conclusion, polymyxin B but not flunixin inhibits the LPS-induced suppression of 
luteal hCG responsiveness, although flunixin successfully inhibits luteal PG secretion. 
Therefore, the detrimental effects of LPS on the bovine CL in the isolated perfused ovary 
were most likely mediated by LPS-induced release of proinflammatory cytokines and 
apoptosis and not by luteolysis due to secretion of luteal PGF2α.  
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Fig. 1. Schematic view of the equipment used for isolated perfusion of bovine ovaries. 
 
Fig. 2. Changes (means ± SEM) in PGE2 (A) and PGF2α (B) concentrations of the effluent 
perfusate from ovaries treated with flunixin and LPS (F-LPS,    ; n=6) and ovaries treated with 
polymyxin B and LPS (PX-LPS,     ; n=6) during the treatment period of perfusion. 
       Treatment with 500 I.U. hCG. 
a Difference (P ≤ 0.05) compared to 0 min after the start of LPS-challenge in the group 
indicated. 
* Difference (P ≤ 0.05) between groups F-LPS and PX-LPS at times indicated. 
 
Fig. 3. Changes (means ± SEM) in P4 concentrations of the effluent perfusate from ovaries 
treated with flunixin and LPS (F-LPS,     ; n=6) and ovaries treated with polymyxin B and 
LPS (PX-LPS,     ; n=6) during the treatment period of perfusion. 
       Treatment with 500 I.U. hCG. 
a,b Difference (P ≤ 0.05) compared to (a) 0 min after the start of LPS-challenge (b) 150 min 
after the start of LPS-challenge (i.e. the time of hCG stimulation) in the group indicated. 
 
Fig. 4. Changes (means ± SEM) in luteal mRNA expression of tumor necrosis factor α 
(TNFA), caspase (CASP) 3, CASP8, prostaglandin E synthase (PGES), and PGFS, of ovaries 
treated with flunixin and LPS (F-LPS, black column; n=6) and ovaries treated with 
polymyxin B and LPS (PX-LPS, grey column; n=6) during the treatment period of perfusion. 





Table 1. Sequences and accession numbers of PCR primers for assayed genes from bovine corpus luteum cells, and length and annealing 
temperature (AT) of PCR products 
Gene Gene symbol Reference Forward primer Reverse primer PCR product AT 
  [acc. no.] [5’-…-3’] [5’-…-3’] [bp] [°C] 
Tumor necrosis factor α TNFA NM_173966.3 CCACGTTGTAGCCGACATC ACCACCAGCTGGTTGTCTTC 108 60 
Caspase 3 CASP3 NM_001077840.1 AACCTCCGTGGATTCAAAATC TTCAGGRTAATCCATTTTGTAAC1 114 60 
Caspase 8 CASP8 NM_001045970.2 TGTCACAATCGCTTCCAGAG GAAGTTCAGGCACCTGCTTC 183 60 
Prostaglandin E synthase PGES (PTGES) NM_174443.2 TCCTGGTCTTCTTCCTGGG CCCAGACAATCTGCAGGG 132 60 
Prostaglandin F synthase PGFS (AKR1B1) NM_001012519.1 ATACAAGCCGGCGGTTAAC TGTCTGCAATCGCTTTGATC 188 60 
Tyrosine 3-monooxygenase/tryptophan 5- 
   monooxygenase activation protein, zeta 
YWHAZ NM_174814.2 AGGCTGAGCGATATGATGAC GACCCTCCAAGATGACCTAC 141 60 
Histone H3F3A NM_001014389.2 ACTGGCTACAAAAGCCGCTC ACTTGCCTCCTGCAAAGCAC 233 60 
CCR4-NOT transcription complex, subunit 11 CNOT11 XM_582695.6 TCAGTGGACCAAAGCCACCTA CTCCACACCGGTGCTGTTCT 170 60 
Suppressor of zeste 12 homolog (Drosophila) SUZ12 NM_001205587.1 CATCCAAAAGGTGCTAGGATAGATG TGGGCCTGCACACAAGAATG 160 60 
TATA box binding protein TBP NM_001075742.1 CAGAGAGCTCCGGGATCGT CACCATCTTCCCAGAACTGAATAT 194 60 































09/1993 – 06/1998 
09/1998 – 06/2002 
09/2002 – 06/2006 
Scuola elementare, Gordola, Schweiz 
Scuola media, Gordola, Schweiz 
Liceo cantonale, Locarno, Schweiz 
  
28.06.2006 Matura, Liceo cantonale, Locarno, Schweiz 
  
09/2008 – 08/2013 Tiermedizin, Vetsuisse Fakultät, Universität Zürich, Schweiz 
  
01/2014 Staatsexamen, Vetsuisse Fakultät, Universität Zürich, Schweiz 
  
03/2014 – 08/2016 Anfertigung der Dissertation  
   unter Leitung von Prof. Dr. Heiner Bollwein 
 an der Klinik für Reproduktionsmedizin der Vetsuisse Fakultät, 
Universität Zürich 
 (Direktor: Prof. Dr. Heiner Bollwein) 
  




Assistentin, Clinica Alpina, Scuol, Schweiz 
 
